A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

clipboard-pencil

About the study

The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:


* Have a body mass index (BMI) of:


  1. ≥30 kilogram per square meter (kg/m2) OR
  2. ≥27 kg/m2 with at least one of the following weight-related conditions: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease
  3. Have at least one unsuccessful attempt to lose weight by dieting

EXCLUSION CRITERIA

Exclusion Criteria:


  1. Have a self-reported change in body weight >5 kg (11 pounds) within 90 days before screening
  2. Have a prior or planned surgical treatment for obesity
  3. Have type 1 diabetes or type 2 diabetes
  4. Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
  5. Have had within the past 90 days before screening

  1. acute myocardial infarction
  2. cerebrovascular accident (stroke)
  3. hospitalization for unstable angina, or
  4. hospitalization due to congestive heart failure
  5. Have New York Heart Association Functional Classification Class IV congestive heart failure
  6. Have a history of chronic or acute pancreatitis
  7. Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.
Phone iconCall 1-317-615-4559Email iconEmail Study Center

Study Details

Contition
Obesity,Overweight
Age
18+
Phase
PHASE3
Participants Needed
250
Est. Completion Date
Jul 31, 2027
Treatment Type
INTERVENTIONAL
Sponsor
Eli Lilly and Company
ClinicalTrials.gov NCT Identifier
NCT07232719
Study Number
J1I-MC-GZQJ

Understanding Clinical Trials

Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?